BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530
The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.
Source: onclive.com